GenturaDx
Luminex CEO Discusses M&A Strategy, Divestiture as Firm Focuses on Existing MDx Developments
Premium
This article was originally posted on Sept. 12.
Luminex has no plans to acquire any new businesses or companies at this time, its CEO Patrick Balthrop said at an investment conference last week.
Luminex this week provided investors with additional details regarding the planned expansion of its molecular diagnostics business to tap into the laboratory-developed test market and to serve customers seeking a platform with higher throughput and lower multiplexing than Luminex
Luminex this week provided investors with an update on its molecular diagnostics pipeline, including the integration of recently acquired GenturaDx and its sample-to-answer testing platform and the market uptake and opportunity for its xTAG Gastrointestinal Pathogen Panel.
Luminex Discloses GenturaDx Loss of $19.8M in 2011, $18.5M in H1 2012
NEW YORK (GenomeWeb News) – Luminex today disclosed the finances of GenturaDx, a molecular diagnostic test firm that it acquired for $50 million during the summer.
Luminex Completes GenturaDx Acquisition
NEW YORK (GenomeWeb News) – Luminex has completed the acquisition of molecular diagnostics firm GenturaDx for $50 million in cash plus potential additional consideration based on milestones and/or product revenue performance.
Jul 12, 2012
Jul 9, 2012
Luminex to Acquire GenturaDx for $50M
Mar 28, 2012
Jan 12, 2012
Nov 9, 2011
Jul 14, 2011
Nov 18, 2010